BIOSIDUS

OVER 30 YEARS

promoting a better quality of life

HEMAX®
Erythropoietin

Neutromax®
Filgrastim
Factor of life

WHY CHOOSE HEMAX®?

Due to its proven efficacy

- Hemax® stimulates erythropoiesis and survival of erythroid lineage cells.[1]
- Hemax® decreases transfusion requirements and their associated risks.[1,2]
    - Risks associated with transfusions include hemolysis, fever, anaphylaxis, acute lung involvement, and several delayed reactions.
- Hemax® improves patients' quality of life.[3]
- Hemax® reduces the risk of hospitalization.[4]



Hemax® in the erythropoiesis process

CFU-E: colony forming unit-erythroid

WHY CHOOSE HEMAX®?

Due to the wide range of approved indications[5]

- ✔ Symptomatic anemia caused by renal disease
- ✔ Anemia secondary to chemotherapy for solid tumors
- ✔ Anemia in adults with myelodysplastic syndrome
- ✔ Moderate anemia due to presurgical autologous blood donation
- ✔ Moderate anemia prior to major orthopedic surgery
- ✔ Anemia in patients receiving zidovudine
- ✔ Anemia in preterm infants with a birth weight between 750-1500 g and a gestational age <34 weeks.

HEMAX® FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME-RELATED ANEMIA

Erythropoiesis-stimulating agents (ESAs) are the **first-line treatment** for lower-risk myelodysplastic syndrome (MDS)-related anemia.[6,7]

- Most patients with MDS develop anemia or anemia-related symptoms, which can impact adversely on their quality of life.[6]
- For patients with MDS, anemia is associated with particularly negative consequences,[8] including chronic fatigue, increased risk of cardiovascular complications, and increased risk of relapse.[7]
- Although blood transfusions can temporarily reduce anemia symptoms, they can also lead to transfusion dependence and iron overload, which are associated with reduced survival and worse quality of life.[8]

Anemia and transfusion dependence are associated with reduced survival in patients with MDS.[6]

Treatment with epoetin alfa reduces the need for transfusions in patients with MDS.[8]

HEMAX® FOR MYELODYSPLASTIC SYNDROME-RELATED ANEMIA

Erythropoiesis-stimulating agents, like Hemax®, are the first-line therapy for lower-risk myelodysplastic syndrome (MDS)-related anemia.[6,7]

The use of high doses of epoetin alfa is recommended for the treatment of anemia in patients with lower-risk MDS.[9,10]

Dosing recommended by international clinical practice guidelines

NCCN[11]	ESMO[12]	ASCO/ASH[13]
40,000-60,000 IU 1-2 weekly (Increase to 60,000 IU/weekly for non-responders 4 weeks after initiation).	30,000-80,000 IU/weekly (Increase to 80,000 IU/weekly for non-responders 4 weeks after initiation).	40,000-60,000 IU/weekly (Increase to 60,000 IU/weekly for non-responders 4 weeks after initiation).

ASCO: American Society of Clinical Oncology; **ASH:** American Society of Hematology; **ESMO:** European Society of Medical Oncology; **NCCN:** National Comprehensive Cancer Network.

- Based on the results of a systematic review and a meta-analysis, treatment with high doses of epoetin alfa results in a significantly higher response rate compared with the standard dose (63.3% *vs* 47.8%; p <0.001).[14]



Response rates for standard and high doses of epoetin alfa

*p < 0.001 compared with respective standard dose.

Adapted from Gascón P, Krendyukov A, *et al*. Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. Leuk Res. 2019 Jun; 81:35-42.

HEMAX® Erythropoietin

HEMAX® FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME-RELATED ANEMIA

- A high percentage of patients with lower-risk MDS will have a positive response to epoetin alfa.[15]

- Different clinical and laboratory factors allow to estimate the probability of response to treatment with epoetin alfa:[9]

	Higher probability of response[9]	Lower probability of response[9]
Diagnosis based on WHO classification	Refractory anemia	Refractory anemia with excess blasts
% of blasts in BM	<5%	>5%
Serum EPO	<500	>500
Transfusions	<2 U/month	>2 U/month
FCM	Normal myeloid progenitors	Abnormal myeloid progenitors
ERK phosphorylation	High	Low

BM: bone marrow; **EPO:** erythropoietin; **ERK:** extracellular signal-regulated kinase; **FCM:** flow cytometry; **WHO:** World Health Organization.

- Timely initiation of treatment with epoetin alfa, before developing transfusion dependence, is associated with a higher response rate.[15]

- In addition to optimal doses and appropriate periods of treatment, it is important to administer epoetin alfa regularly and without interruptions in order to maintain stable levels of hemoglobin.[15]

HEMAX® FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME-RELATED ANEMIA

Benefits of treatment with Hemax®

- Treatment with epoetin alfa has shown to **improve hemoglobin levels and to reduce transfusion requirements**, with an overall duration of response of 18-24 months.[16]
- Some study results even suggest that treatment with epoetin alfa could **extend survival** in patients with lower-risk MDS.[9]

Safety of treatment with Hemax®

- Patients with lower-risk MDS receiving epoetin alfa did not experience an increase of thrombotic events compared with untreated patients, in contrast to other hematological malignancies.[15]
- Treatment with epoetin alfa has not been associated with hypertension, cardiovascular disorders, or seizures among these patients.[9]
- There was no evidence of a higher risk of disease progression or leukemic transformation.[16]

WHY CHOOSE HEMAX®?

Due to its extensive experience and background

Leading brand in the erythropoietin market

The only lyophilized erythropoietin in the market

<5% of adverse events reported in clinical trials[2]

Over 30 years of experience in the Argentine market

The only erythropoietin not requiring cold chain

Available in over **35 countries**

LEADER FOR ITS PROVEN HIGH QUALITY, RELIABILITY, AND SAFETY

BOXES OF 1 DOSE

- Hemax® 1000 IU*
- Hemax® 2000, 3000, 4000, 10,000, 20,000, and 40,000 IU**

BOXES OF 25 DOSES

- Hemax® 2000, 3000, and 4000***

*Presentation: vial with lyophilized powder + ampoule with diluent + tuberculin syringe + 2 needles and package insert
** Presentations: vial with lyophilized powder + ampoule with diluent + Rymco pack (disposable plastic syringe + 2 needles) and package insert
*** Boxes containing 25 vials with lyophilized powder and 25 ampoules with diluent.

HEMAX® Erythropoietin

WHY CHOOSE NEUTROMAX®?

Due to its proven efficacy[17]



Neutromax® mechanism of action

Adapted from Rutella S, *et al.* J Immunol. 2005; 175(11): 7085-7091.
*NK: natural killer

Due to its extensive experience

Leading brand in the Argentine market

Local and regional **high-quality standards**

>25 countries where Neutromax® is registered and marketed

Indicated for multiple etiologies of neutropenia

Neutromax® Filgrastim
Factor of life

WHY CHOOSE NEUTROMAX®?

Due to the wide range of approved indications[17,18]

- Neutromax® is highly effective in primary and secondary neutropenia
- Neutromax® increases the number of mature neutrophils
- Neutromax® reduces the duration of severe neutropenia
- Neutromax® decreases life-threatening infections, length of hospitalization, and morbimortality associated with severe neutropenia
- Neutromax® is beneficial for minimizing the impact of chemotherapy-induced neutropenia
- Neutromax® accelerates the recovery of the absolute neutrophil count in the treatment of hematological malignancies and bone marrow transplants
- Neutromax® improves neutrophil levels in patients with neutropenia associated with multiple etiologies

Neutromax® is a great ally for reducing the risk of severe or febrile neutropenia

ONCOLOGY PATIENTS
Cancer patients receiving myelosuppressive CT
Patients with AML treated with induction or consolidation CT
Patients with malignancies requiring bone marrow transplant

OTHER INDICATIONS
Mobilization of hematopoietic stem cells into peripheral blood
Patients with chronic severe neutropenia
Patients exposed to myelosuppressive doses of radiation
AIDS-related neutropenia

WHY CHOOSE NEUTROMAX®?

Due to its safety[19]

- Tolerance to filgrastim in real-world patients with neutropenia:[20]
  - "Very good" tolerance in the application site (63.3% of cases).
  - Less than 2% of patients discontinue treatment due to poor tolerance.
  - Less than 3% of adverse events are considered as severe.

LEADER FOR ITS PROVEN HIGH QUALITY, RELIABILITY, AND SAFETY

- Neutromax® 300 µg (30 MU): boxes containing 1 or 5 vials x 1 mL
- Neutromax® 480 µg (48 MU): boxes containing 5 vials x 1.6 mL

Neutromax® Filgrastim
Factor de vida

References: 1. Vittori D, Chamorro ME, Nesse A. Eritropoyetina como agente eritropoyético y no eritropoyético: consideraciones terapéuticas. Acta Bioquím Clín Latinoam. 2016; 50(4): 773-782. **2.** Carman M, Schieferle-Uhlenbrock J, McClintock SM. CE: A Review of Current Practice in Transfusion Therapy. Am J Nurs. 2018; 118(5): 36-44. **3.** Park S, Greenberg P, Yucel A, *et al*. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019; 184(2): 134-160. **4.** Zhou S, Zhuang Y, Zhao W, *et al.* Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia. Experimental and Therapeutic Medicine. 2014; 8(3): 863-870. **5.** Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). Disposición 4763/2019. **6.** Platzbecker U, Kubasch AS, *et al*. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182-2198. **7.** Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020 Jun;189(6):1016-1027. **8.** Pa-rk S, Greenberg P, *et al.* Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019 Jan;184(2):134-160. **9.** Ferro H. Actualización del uso de factores hematopoyéticos en hematología. Hematología. 2015; 19:12-19. **10.** Síndromes mielodisplásicos y síndromes de superposición mielodisplasia/neoplasia mieloproliferativa. Sociedad Argentina de Hematología. Disponible en: http://www.sah.org.ar/docs/2019/Sindromes_Mielodisplasicos_y_Sindromes_de_Superposicion_Mielodisplasia_Neoplasia_Mieloproliferativa.pdf **11.** NCCN Guidelines Version 3.2022. Myelodysplastic Syndromes. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf **12.** Fenaux P, Haase D, *et al.*; ESMO Guidelines Committee. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Feb;32(2):142-156. **13.** Bohlius J, Bohlke K, *et al*. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019 May 20;37(15):1336-1351. **14.** Gascón P, Krendyukov A, *et al.* Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. Leuk Res. 2019 Jun;81:35-42. **15.** Santini V. Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2016;2016(1):462-469. **16.** Hellström-Lindberg E, Tobiasson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020 Jul;105(7):1765-1779. **17.** Dale DC, Crawford J, Klippel Z, *et al*. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018; 26(1): 7-20. **18.** Prospecto de Neutromax®, disponible en: https://bit.ly/3kWFA9I (consultado en agosto de 2022). **19.** Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). Disposición 4763/2019. **20.** Otremba B, Hielscher C, Petersen V, *et al.* Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia. Patient Preference and Adherence. 2018; 12: 2179–2186.

Scan the QR code to see package insert

HEMAX® Erythropoietin

Scan the QR code to see package insert

Neutromax® Filgrastim

Factor of life

This material is exclusive to HCPs; do not distribute to the general public.

BIOSIDUS

Building a healthier future

BIOSIDUS S.A.U. | Constitución 4234 (C1254ABX) CABA, **Corporate Office:** Cazadores de Coquimbo 2841, Bldg. 4, 1st Floor (B1605AZE) Munro, Buenos Aires | +5411 4909 8000. info@biosidus.com.ar | www.biosidus.com.ar